Literature DB >> 18469113

Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone.

Noriyuki Homma1, Tetsutaro Nagaoka, Vijaya Karoor, Masatoshi Imamura, Laimute Taraseviciene-Stewart, Lori A Walker, Karen A Fagan, Ivan F McMurtry, Masahiko Oka.   

Abstract

RhoA/Rho kinase (ROCK) signaling plays a key role in the pathogenesis of experimental pulmonary hypertension (PH). Dehydroepiandrosterone (DHEA), a naturally occurring steroid hormone, effectively inhibits chronic hypoxic PH, but the responsible mechanisms are unclear. This study tested whether DHEA was also effective in treating monocrotaline (MCT)-induced PH in left pneumonectomized rats and whether inhibition of RhoA/ROCK signaling was involved in the protective effect of DHEA. Three weeks after MCT injection, pneumonectomized rats developed PH with severe vascular remodeling, including occlusive neointimal lesions in pulmonary arterioles. In lungs from these animals, we detected cleaved (constitutively active) ROCK I as well as increases in activities of RhoA and ROCK and increases in ROCK II protein expression. Chronic DHEA treatment (1%, by food for 3 wk) markedly inhibited the MCT-induced PH (mean pulmonary artery pressures after treatment with 0% and 1% DHEA were 33+/-5 and 16+/-1 mmHg, respectively) and severe pulmonary vascular remodeling in pneumonectomized rats. The MCT-induced changes in RhoA/ROCK-related protein expression were nearly normalized by DHEA. A 3-wk DHEA treatment (1%) started 3 wk after MCT injection completely inhibited the progression of PH (mean pulmonary artery pressures after treatment with 0% and 1% DHEA were 47+/-3 and 30+/-3 mmHg, respectively), and this treatment also resulted in 100% survival in contrast to 30% in DHEA-untreated rats. These results suggest that inhibition of RhoA/ROCK signaling, including the cleavage and constitutive activation of ROCK I, is an important component of the impressive protection of DHEA against MCT-induced PH in pneumonectomized rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18469113      PMCID: PMC2494797          DOI: 10.1152/ajplung.90251.2008

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  61 in total

Review 1.  Rocks: multifunctional kinases in cell behaviour.

Authors:  Kirsi Riento; Anne J Ridley
Journal:  Nat Rev Mol Cell Biol       Date:  2003-06       Impact factor: 94.444

2.  Dietary dehydroepiandrosterone inhibits bone marrow and leukemia cell transplants: role of food restriction.

Authors:  Fernando Catalina; Leon Milewich; Vinay Kumar; Michael Bennett
Journal:  Exp Biol Med (Maywood)       Date:  2003-12

3.  Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase activity and gene expression by dehydroepiandrosterone in preneoplastic liver nodules.

Authors:  R M Pascale; M M Simile; M R De Miglio; A Nufris; M A Seddaiu; M R Muroni; O Danni; K N Rao; F Feo
Journal:  Carcinogenesis       Date:  1995-07       Impact factor: 4.944

4.  Evidence that estrogen suppresses rho-kinase function in the cerebral circulation in vivo.

Authors:  Sophocles Chrissobolis; Klaudia Budzyn; Philip D Marley; Christopher G Sobey
Journal:  Stroke       Date:  2004-07-15       Impact factor: 7.914

5.  Dehydroepiandrosterone-sulfate inhibits nuclear factor-kappaB-dependent transcription in hepatocytes, possibly through antioxidant effect.

Authors:  Yasumasa Iwasaki; Masato Asai; Masanori Yoshida; Takeshi Nigawara; Machiko Kambayashi; Nobuo Nakashima
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

Review 6.  Pathologic assessment of vasculopathies in pulmonary hypertension.

Authors:  Giuseppe G Pietra; Frederique Capron; Susan Stewart; Ornella Leone; Marc Humbert; Ivan M Robbins; Lynne M Reid; R M Tuder
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

7.  Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells.

Authors:  Junko Hiroki; Hiroaki Shimokawa; Midoriko Higashi; Keiko Morikawa; Tadashi Kandabashi; Natsumi Kawamura; Toru Kubota; Toshihiro Ichiki; Mutsuki Amano; Kozo Kaibuchi; Akira Takeshita
Journal:  J Mol Cell Cardiol       Date:  2004-08       Impact factor: 5.000

8.  Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.

Authors:  Kohtaro Abe; Hiroaki Shimokawa; Keiko Morikawa; Toyokazu Uwatoku; Keiji Oi; Yasuharu Matsumoto; Tsuyoshi Hattori; Yutaka Nakashima; Kozo Kaibuchi; Katsuo Sueishi; Akira Takeshit
Journal:  Circ Res       Date:  2003-12-11       Impact factor: 17.367

9.  Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.

Authors:  Toshihiko Nishimura; Laszlo T Vaszar; John L Faul; Guohua Zhao; Gerald J Berry; Lingfang Shi; Daoming Qiu; Gail Benson; Ronald G Pearl; Peter N Kao
Journal:  Circulation       Date:  2003-09-08       Impact factor: 29.690

10.  Attenuation of chronic hypoxic pulmonary hypertension by simvastatin.

Authors:  Reda E Girgis; Dechun Li; Xinhua Zhan; Joe G N Garcia; Rubin M Tuder; Paul M Hassoun; Roger A Johns
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-15       Impact factor: 4.733

View more
  35 in total

1.  Effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in proximal and distal pulmonary arterial structure and function.

Authors:  Rebecca R Vanderpool; Ah Ram Kim; Robert Molthen; Naomi C Chesler
Journal:  J Appl Physiol (1985)       Date:  2010-11-18

Review 2.  Pulmonary hypertension in women.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-11

Review 3.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 4.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

5.  Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat.

Authors:  David B Casey; Adeleke M Badejo; Jasdeep S Dhaliwal; James L Sikora; Alex Fokin; Neel H Golwala; Anthony J Greco; Subramanyam N Murthy; Bobby D Nossaman; Albert L Hyman; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-30       Impact factor: 4.733

6.  Estrogen rescues preexisting severe pulmonary hypertension in rats.

Authors:  Soban Umar; Andrea Iorga; Humann Matori; Rangarajan D Nadadur; Jingyuan Li; Federica Maltese; Arnoud van der Laarse; Mansoureh Eghbali
Journal:  Am J Respir Crit Care Med       Date:  2011-06-23       Impact factor: 21.405

7.  The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase.

Authors:  Hui-Hsuan Chung; Zen-Kong Dai; Bin-Nan Wu; Jwu-Lai Yeh; Chee-Yin Chai; Koung-Shing Chu; Chung-Pin Liu; Ing-Jun Chen
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

8.  Activation of glucose-6-phosphate dehydrogenase promotes acute hypoxic pulmonary artery contraction.

Authors:  Rakhee S Gupte; Dhawjbahadur K Rawat; Sukrutha Chettimada; Donna L Cioffi; Michael S Wolin; William T Gerthoffer; Ivan F McMurtry; Sachin A Gupte
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

9.  Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men.

Authors:  Corey E Ventetuolo; Grayson L Baird; R Graham Barr; David A Bluemke; Jason S Fritz; Nicholas S Hill; James R Klinger; Joao A C Lima; Pamela Ouyang; Harold I Palevsky; Amy J Palmisciano; Ipsita Krishnan; Diane Pinder; Ioana R Preston; Kari E Roberts; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2016-05-15       Impact factor: 21.405

10.  Signaling through Rho GTPase pathway as viable drug target.

Authors:  Qun Lu; Frank M Longo; Huchen Zhou; Stephen M Massa; Yan-Hua Chen
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.